Circulating microRNA-196a is an early gastric cancer biomarker
Metrics: PDF 1289 views | HTML 1798 views | ?
Tsung-Hsing Chen1,2, Chieh Lee3, Cheng-Tang Chiu1, Yin-Yi Chu1, Hao-Tsai Cheng1, Jun-Te Hsu4, Yung-Kuan Tsou1, Ren-Chin Wu5, Tse-Ching Chen5, Nien-Chen Chang6, Ta-Sen Yeh4 and Kwang-Huei Lin6,7,8
1Department of Gastroenterology and Hepatology, Linkou Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taoyuan, Taiwan
2Graduate Institute of Clinical Medical Sciences, Chang Gung University, Taoyuan, Taiwan
3Department of Industrial Engineering and Management, Yuan Ze University College of Engineering, Chung-Li City, Taiwan
4Department of Surgery, Chang Gung Memorial Hospital, Linkou, Chang Gung University College of Medicine, Taoyuan, Taiwan
5Department of Pathology, Linkou Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taoyuan, Taiwan
6Graduate Institute of Biomedical Sciences, Chang Gung University, Taoyuan, Taiwan
7Liver Research Center, Chang Gung Memorial Hospital, Linkou, Taoyuan, Taiwan
8Research Center for Chinese Herbal Medicine, College of Human Ecology, Chang Gung University of Science and Technology Taoyuan, Taiwan
Kwang-Huei Lin, email: [email protected]
Ta-Sen Yeh, email: [email protected]
Keywords: microRNA-196a; precancerous gastric lesions; early gastric cancer; intestinal metaplasia; dysplasia
Received: April 11, 2017 Accepted: November 15, 2017 Published: December 07, 2017
MicroRNA-196a (miRNA-196a) is associated with the development of gastric cancer and metastasis. Intestinal metaplasia and low- or high-grade dysplasia are considered to be precursors of intestinal type gastric cancer. Accordingly, we investigated the expression of plasma miRNA-196a as an early detection biomarker in precancerous gastric lesions and early cancer (pT1a/b), which is otherwise treated with endoscopic submucosal dissection. Our data showed that levels of circulating (plasma) miRNA-196a were higher in patients with precancerous lesions/early gastric adenocarcinoma than in healthy controls. The area under the receiver operating characteristic curve (AUC) for healthy controls vs. intestinal metaplasia was 0.9736; healthy controls vs. low-grade/high-grade dysplasia 0.9495; and healthy controls vs. early gastric cancer 0.9318. These results indicate that circulating miRNA-196a is a novel biomarker for detection of early gastric cancer and its precursor.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.